Material Detail

Glioblastoma (GBM) is a highly aggressive cancer with a poor prognosis in need of improved treatment modalities. The lack of reliable biomarkers to predict treatment response and outcome further complicates the case. Although several molecular markers have been proposed, their integration into clinical settings is hindered by marker heterogeneity. To address this, a systematic review and meta-analysis were conducted to evaluate the prognostic...

Disciplines:

• Health Sciences  / Cancer  / Cancer diagnosis

More...